Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

In Meraouna et al.'s study, the failure-free survival rate was 66% at 3 years of follow-up. Regarding treatment-related morbidities, 12.3% of patients experienced grade 3 genitourinary (GU) toxicity, ...

External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Beam Therapeutics Inc. (BEAM) been one of those stocks this ...

Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the ...

The following is a summary of “Brachytherapy Seed Placement by Robotic Bronchoscopy with Cone-Beam CT Guidance for Peripheral ...